Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 235 entries
View as:

A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype

Phase: N/A Priority: Normal
NCT ID: NCT01358370 Org: User:
Start: 11/30/10 End: 03/31/13 Due: 03/31/14

Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection

Phase: N/A Priority: Normal
NCT ID: NCT00034359 Org: User:
Start: 02/28/02 End: 01/31/03 Due: 01/31/04

Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)

Phase: N/A Priority: Normal
NCT ID: NCT02145182 Org: User:
Start: 08/21/14 End: 11/22/16 Due: 11/22/17

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

Phase: N/A Priority: Normal
NCT ID: NCT03459443 Org: User:
Start: 06/20/18 End: 03/29/21 Due: 03/29/22

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)

Phase: N/A Priority: Normal
NCT ID: NCT00838513 Org: User:
Start: 07/31/09 End: 12/31/13 Due: 12/31/14

Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase: N/A Priority: Normal
NCT ID: NCT02598583 Org: User:
Start: 11/12/15 End: 03/11/21 Due: 03/11/22

To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients

Phase: N/A Priority: Normal
NCT ID: NCT01755429 Org: User:
Start: 05/31/12 End: 07/31/12 Due: 07/31/13

Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase: N/A Priority: Normal
NCT ID: NCT01335165 Org: User:
Start: 04/30/11 End: 03/31/14 Due: 03/31/15

Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05641311 Org: User:
Start: 02/20/19 End: 05/02/19 Due: 05/02/20

Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients

Phase: N/A Priority: Normal
NCT ID: NCT02273596 Org: User:
Start: 11/24/14 End: 11/07/18 Due: 11/07/19

Study of ALXN2050 in Participants With Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT05259085 Org: User:
Start: 04/07/22 End: 08/12/24 Due: 08/12/25

A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease

Phase: N/A Priority: Normal
NCT ID: NCT02245412 Org: User:
Start: 11/14/14 End: 02/27/17 Due: 02/27/18

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

Phase: N/A Priority: Normal
NCT ID: NCT00401947 Org: User:
Start: 11/30/06 End: 03/31/07 Due: 03/31/08

Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation

Phase: N/A Priority: Normal
NCT ID: NCT00312039 Org: User:
Start: 03/31/06 End: 10/31/07 Due: 10/31/08

A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)

Phase: N/A Priority: Normal
NCT ID: NCT02329327 Org: User:
Start: 04/10/15 End: 09/24/20 Due: 09/24/21

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05307978 Org: User:
Start: 04/12/22 End: 02/07/23 Due: 02/07/24

Danicopan Early Access Program

Phase: N/A Priority: Normal
NCT ID: NCT05982938 Org: User:
Start: - End: - Due: -

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase: N/A Priority: Normal
NCT ID: NCT06578949 Org: User:
Start: 10/10/24 End: 01/14/26 Due: 01/14/27

A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT03384186 Org: User:
Start: 12/01/17 End: 03/21/18 Due: 03/21/19

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT06967480 Org: User:
Start: 06/13/25 End: 05/31/27 Due: 05/31/28

A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)

Phase: N/A Priority: Normal
NCT ID: NCT01419028 Org: User:
Start: 08/31/12 End: 02/28/14 Due: 02/28/15

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Phase: N/A Priority: Normal
NCT ID: NCT03056040 Org: User:
Start: 05/17/17 End: 02/21/22 Due: 02/21/23

An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT02376751 Org: User:
Start: - End: - Due: -

Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase: N/A Priority: Normal
NCT ID: NCT00867932 Org: User:
Start: 10/02/09 End: 05/12/11 Due: 05/12/12

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

Phase: N/A Priority: Normal
NCT ID: NCT05966467 Org: User:
Start: 02/01/24 End: 03/04/30 Due: 03/04/31